BlackRock Amends Enanta Pharma Stake, Signals Continued Confidence
Ticker: ENTA · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**BlackRock still a major holder in Enanta Pharma, good sign for stability.**
AI Summary
BlackRock, Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating a change in their ownership of Enanta Pharmaceuticals Inc. common stock as of December 31, 2023. This filing, Amendment No. 4, shows that BlackRock continues to be a significant institutional investor in Enanta Pharmaceuticals, a pharmaceutical preparations company. This matters to investors because large institutional holdings like BlackRock's can signal confidence in the company's long-term prospects and provide a degree of stability to the stock price.
Why It Matters
This filing confirms BlackRock's ongoing significant investment in Enanta Pharmaceuticals, which can influence investor perception and stock stability.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative risks.
Analyst Insight
Investors should note BlackRock's continued presence as a major shareholder, which suggests institutional confidence in Enanta Pharmaceuticals. While this filing doesn't provide new financial data, it reinforces the stability of the institutional ownership base.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Enanta Pharmaceuticals Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 4 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 4)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as indicated under '(1)Names of reporting persons. BlackRock, Inc.' and in the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company whose securities are being reported?
The subject company is ENANTA PHARMACEUTICALS INC, as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC' and '(Name of Issuer) ENANTA PHARMACEUTICALS INC'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Enanta Pharmaceuticals Inc. is 29251M106, as listed under '(CUSIP Number) 29251M106'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding ENANTA PHARMACEUTICALS INC (ENTA).